The Prevalence, Risk Factors, and Prognostic Value of Venous Thromboembolism in Ovarian Cancer Patients Receiving Chemotherapy: a Systematic Review and Meta-analysis

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2021 Jan 14

PMID 33441137

Citations 6

Authors

Lu Ye

Li Cai

Yonghui Fu

Debao Zhuang

Xiaoqing Hu

Youkun Jie

Affiliations

Soon will be listed here.

Abstract

Background: Venous thromboembolism (VTE) in ovarian cancer (OC) patients has been widely investigated, but our knowledge on the role of VTE in OC patients receiving chemotherapy is limited. The aim of our study was to investigate the prevalence, risk factors, and prognostic value of chemotherapy-associated VTE in OC.

Methods: Three databases (PubMed, Embase, and the Cochrane Library) were systematically searched from inception to October 14, 2020. The primary outcome was the prevalence of VTE in OC patients receiving chemotherapy. The risk factors and prognostic value of VTE were the secondary outcomes. The pooled prevalence of VTE was estimated using the generic inverse-variance method. The statistical heterogeneity was evaluated with Cochran's Q test and I statistic. Funnel plot, Begg's test, and Egger's test were used to assess the potential publication bias in the meta-analysis.

Results: A total of eleven observational studies with 4759 OC patients were included. The pooled prevalence of VTE was 9% (95% CI, 0.06-0.12) in OC patients receiving chemotherapy. The results of subgroup analysis and sensitivity analysis were basically consistent with the overall pooled estimate. Multiple significant risk factors associated with VTE were also identified including advanced age, D-dimer > 0.5 mg/mL, and tumor diameter > 10 cm. Only two included studies reported the prognostic value of VTE in OC patients receiving chemotherapy, but with inconsistent results. Funnel plot showed that there existed potential publication bias, which was further verified by statistical test, but the results of the trim-and-fill method showed the pooled estimate kept stable after adding two "missing" studies.

Conclusions: This current study revealed that the pooled prevalence of chemotherapy-related VTE in OC was approximately 9% in OC patients. Risk factors for chemotherapy-related VTE were also identified which may contribute to targeting potentially preventative measures for VTE in OC.

Citing Articles

Incidence and risk factors of silent deep venous thromboembolism before interval debulking surgery in ovarian cancer patients, a tertiary centre experience.

Abdelkhalek M, Refky B, Zuhdy M, Hamdy O, Hamdy M, Gaballa K Gynecol Oncol Rep. 2024; 56:101522.

PMID: 39435257 PMC: 11493189. DOI: 10.1016/j.gore.2024.101522.

Prognostic value of pretreatment platelet count, fibrinogen and d-dimer levels in osteosarcoma patients: A meta-analysis.

Li X, Ren H, Peng L, Li J Medicine (Baltimore). 2024; 103(22):e38463.

PMID: 39259059 PMC: 11142833. DOI: 10.1097/MD.0000000000038463.

Incidence and risk factors for venous thromboembolism in patients with ovarian cancer during neoadjuvant chemotherapy: a meta-analysis.

Han L, Chen Y, Zheng A, Chen H Am J Cancer Res. 2023; 13(5):2126-2134.

PMID: 37293158 PMC: 10244120.

The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors.

Mei R, Wang G, Chen R, Wang H World J Surg Oncol. 2022; 20(1):245.

PMID: 36058927 PMC: 9442986. DOI: 10.1186/s12957-022-02705-z.

Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.

Tamura R, Yoshihara K, Enomoto T Cancers (Basel). 2022; 14(9).

PMID: 35565252 PMC: 9099459. DOI: 10.3390/cancers14092125.

References

Stampfli S, Akhmedov A, Gebhard C, Lohmann C, Holy E, Rozenberg I . Aging induces endothelial dysfunction while sparing arterial thrombosis. Arterioscler Thromb Vasc Biol. 2010; 30(10):1960-7. DOI: 10.1161/ATVBAHA.110.206920. View

Fotopoulou C, duBois A, Karavas A, Trappe R, Aminossadati B, Schmalfeldt B . Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008; 26(16):2683-9. DOI: 10.1200/JCO.2008.16.1109. View

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

Salinaro J, McQuillen K, Stemple M, Boccaccio R, Ehrisman J, Lorenzo A . Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2020; 30(4):491-497. DOI: 10.1136/ijgc-2019-000980. View

Fotopoulou C, Karavas A, Trappe R, Chekerov R, Lichtenegger W, Sehouli J . Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). Thromb Res. 2009; 124(5):531-5. DOI: 10.1016/j.thromres.2009.03.013. View

Pellino G, Sciaudone G, Candilio G, De Fatico G, Canonico S, Selvaggi F . Predictors of Venous Thromboembolism after Colorectal Surgery in a Single Unit. Acta Chir Belg. 2015; 115(4):288-92. DOI: 10.1080/00015458.2015.11681114. View

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Lawrie T, Winter-Roach B, Heus P, Kitchener H . Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015; (12):CD004706. PMC: 6457737. DOI: 10.1002/14651858.CD004706.pub5. View

Chavan D, Huang Z, Song K, Parimi L, Yang X, Zhang X . Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer. Medicine (Baltimore). 2017; 96(42):e7935. PMC: 5662354. DOI: 10.1097/MD.0000000000007935. View

10.

Wattanakit K, Lutsey P, Bell E, Gornik H, Cushman M, Heckbert S . Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost. 2012; 108(3):508-15. PMC: 3482827. DOI: 10.1160/TH11-10-0726. View

11.

Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski M, Gaca M . Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab. Target Oncol. 2017; 12(4):495-503. PMC: 5524869. DOI: 10.1007/s11523-017-0496-3. View

12.

Zhou Q, Zhu C, Shen Z, Zhang T, Li M, Zhu J . Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. Eur J Surg Oncol. 2020; 46(5):855-861. DOI: 10.1016/j.ejso.2020.01.026. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M . Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer. 2019; 22(5):988-998. DOI: 10.1007/s10120-019-00930-2. View

15.

Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X . Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine (Baltimore). 2017; 96(25):e7062. PMC: 5484191. DOI: 10.1097/MD.0000000000007062. View

16.

Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T . Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol. 2019; 153(3):589-596. PMC: 7526703. DOI: 10.1016/j.ygyno.2019.03.243. View

17.

Greco P, Bazzi A, McLean K, Reynolds R, Spencer R, Johnston C . Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Obstet Gynecol. 2017; 129(6):979-985. DOI: 10.1097/AOG.0000000000001980. View

18.

Mittal V, Ahuja S, Vejella S, Stempel J, Palabindala V, Dourado C . Trends and Outcomes of Venous Thromboembolism in Hospitalized Patients With Ovarian Cancer: Results From Nationwide Inpatient Sample Database 2003 to 2011. Int J Gynecol Cancer. 2018; 28(8):1478-1484. DOI: 10.1097/IGC.0000000000001335. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Shi L, Lin L . The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019; 98(23):e15987. PMC: 6571372. DOI: 10.1097/MD.0000000000015987. View